Cover Image
市場調查報告書

美國的MA (醫療事務) 部門的評估:非小細胞肺癌

Medical Affairs Reputations Non-small Cell Lung Cancer US

出版商 FirstWord 商品編碼 358485
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的MA (醫療事務) 部門的評估:非小細胞肺癌 Medical Affairs Reputations Non-small Cell Lung Cancer US
出版日期: 2016年03月01日 內容資訊: 英文
簡介

本報告以非小細胞肺癌治療藥的主要8個產品相關的醫療事務 (MA) 團隊上,美國的100名癌症專門醫生為對象加以調查,彙整其對各公司團隊的效能及滿意度評分及排行榜,醫生的服務利用趨勢,要求,改善地方等分析。

對象的企業·品牌

  • Avastin (Bevacizumab:Roche)
  • Gilotrif (afachinibu:Boehringer Ingelheim)
  • Iressa (Gefitinib:AstraZeneca)
  • Keytruda (penburorizumabu:Merck & Co.)
  • Opdivo (niborumabu:Bristol-Myers Squibb)
  • Tarceva (厄洛替尼 :Roche)
  • Xalkori (Crizotinib:Pfizer/EMD Serono)
  • Zykadia (serichinibu:Novartis)

調查·分析內容範例

  • MA隊的利用方法·頻率
  • 一般認為最重要的服務
  • 聯繫的頻率和偏好的途徑
  • 醫生對各團隊的印象
  • 各隊伍的效能·滿意度:12項
  • 醫生的需求與服務的改善點
目錄
Product Code: 596200602

Top medical affairs team safely ahead, but competition for 2nd and 3rd place is fierce

In the US non-small cell lung cancer (NSCLC) treatment market, competition among medical affairs teams is fierce. The top team may be comfortably ahead, but the two 2nd-place contenders are running a dead heat, and four more teams are fighting it out for 3rd place. Where does that leave your team?

Are you giving oncologists the services they want most? Are you available when and where they need you? What can you do to boost your team's performance, and stand out from the competition?

Answering Key Questions about Medical Affairs Teams for 8 Major NSCLC Brands

  • Avastin (bevacizumab; Roche) : Satisfaction scores for Avastin's team lag in one key area. Which one?
  • Gilotrif (afatinib; Boehringer Ingelheim) : Gilotrif's overall quality score is within a point of three other teams' scores. Which ones?
  • Iressa (gefitinib; AstraZeneca) : Does Iressa's team earn higher satisfaction scores for responding promptly to medical inquiries or providing relevant resources and materials?
  • Keytruda (pembrolizumab; Merck & Co.) : In which important area does Keytruda's team outperform two of the leading teams?
  • Opdivo (nivolumab; Bristol-Myers Squibb) : Which team's satisfaction scores are consistently highest; Opdivo's, Keytruda's, or Avastin's?
  • Tarceva (erlotinib; Roche) : Tarceva's team earned a top-three satisfaction score in two key areas. Which two?
  • Xalkori (crizotinib; Pfizer/EMD Serono) : Which team responds faster to medical inquiries; Xalkori's, Opdivo's, or Keytruda's?
  • Zykadia (ceritinib; Novartis) : Zykadia's team earns high satisfaction scores in a few areas. But are those areas important to oncologists?

Top Takeaways

  • Leading team is way out front: Ranking far ahead of the rest for overall quality of interactions, despite a competing team's higher performance scores.
  • Second place a dead heat: A mere tenth of a point separates the 2nd and 3rd place teams, though neither comes close to the market leader.
  • Highly competitive treatment area: Performance scores are generally high, and even the lowest ranking team scores relatively well for overall quality of interactions.
  • Top team is also the most active: Significantly more oncologists report interacting with the top brand's medical affairs team in the last 6 months.
  • Solid performance in important areas: Most teams are doing well in areas oncologists consider important, but many still have specific improvements to make.
  • Email surprisingly popular: While US oncologists show little interest in other digital interactions, email is more popular in the US NSCLC market than in others.
  • Feedback points to good relationships: Although oncologists identified several areas where teams can improve, very few thought they needed to improve communication.
  • Clinical support is top priority: The most important medical affairs services for US oncologists all have to do with providing scientific, clinical, and product information.

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams-answering important questions like:

What do oncologists need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with oncologists?
  • How do oncologists rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to oncologists?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Oncologists

We surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with NSCLC in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the last 6 months.

We conducted the survey between January 28th and February 9th, 2016.

Back to Top